Blood test may personalize ovarian cancer care after surgery

NCT ID NCT07546578

Ongoing Knowledge-focused Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a blood test that looks for tiny bits of tumor DNA (called ctDNA) can help doctors decide who needs extra treatment after ovarian cancer surgery. Researchers will analyze stored blood samples from 50 patients taken before and after surgery. The goal is to see if the test can spot patients at higher risk of the cancer coming back, which could lead to more personalized care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ctDNA blood test (liquid biopsy)
What this could lead to: If successful, this could lead to a more personalized approach to decide who needs chemotherapy after ovarian cancer surgery, potentially avoiding unnecessary treatment.
What could go wrong: This is a small, retrospective study using stored samples, not a treatment trial. It may not prove that ctDNA testing improves outcomes, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIQUID BIOPSY OVARIAN CANCER

Contacts and locations

Locations

Policlinico Universitario A. Gemelli IRCCS

Roma, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.